Ophthalmic Telemedicine Market By Component (Hardware, Platform/Solutions, Services) By Therapeutic Indication (Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Retinopathy of Prematurity (ROP), Others), By Application (Vision Testing, Diagnosis and Consultation, Education and Training, Others) By End User (Hospitals, Ophthalmology Clinics, Others) By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Patients can now obtain a rising number of medical services without having to be in the same room as the provider, due to technological advancements in telemedicine in recent years. These developments are enabling new options for patients, especially those who reside in rural areas or may not otherwise be able to visit a practitioner, to obtain eye care from remote diabetic retinopathy screenings to online refraction. Ophthalmologists can now diagnose and treat a wide range of urgent and chronic eye diseases due to the development and availability of powerful hardware, advanced software and quick communication technologies. Moreover, the simultaneous development of numerous digital and telecommunications technologies has created a formerly chance for ophthalmology to adapt to new treatment models based on tele-health and digital breakthroughs. Artificial intelligence (AI), 5th generation (5G) telecommunication networks, and the Internet of Things (IoT) are among the digital breakthroughs that have created an interdependent ecosystem that has allowed new models for opthalmic telemedicine to emerge and also showcases positive growth prospects for ophthalmic telemedicine market to flourish over the forecast period.
Due to of the possibility of viral transmission, governments and health-care establishments were forced to strictly restrict person-to-person interactions during the COVID epidemic. As a result, healthcare practitioners found it difficult to provide treatment to patients who were far away, especially for ophthalmology patients', who had limited access to care. In order to overcome the challenges of in-person inspection, ophthalmic telemedicine innovation expanded at a fast pace, allowing ophthalmologists to provide ongoing treatment to their patients, even an efficient and safe manner. The trends which emerged as a need-of-the-hour technology has been appreciated by healthcare professionals and patients globally. Moreover, healthcare facilities are inclined to continue hybrid mode of ophthalmic treatment alternatives for their patients in the long run. The rapid adoption of the solutions is profusely driving the growth of global ophthalmic telemedicine market.
Global ophthalmic telemedicine market is estimated to grow at a CAGR of 10.5% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Ophthalmic Telemedicine Market Revenue & Forecast, (US$ Million), 2015 – 2030
Component Outlook:
Based on component, the global ophthalmic telemedicine market is segmented into hardware, platform/solutions, and services. Platform and solution segment accounted for the highest share in the market in the year 2021. Visual impairment is becoming increasingly common around the world. By 2040, 288 million people are expected to have vision impairment or other disorders. As the world's population ages, eye health facilities are struggling to address these eye disorders with present manpower and infrastructure and are confronting substantial financial restrictions. In order to overcome these hurdles new ophthalmic telemedicine platforms and models for digital health technology and platforms for ophthalmic care are being incorporated on a large scale. Numerous novel ophthalmic telemedicine solutions and service models, such as secure telemedicine platforms that can be combined with automated algorithms using artificial intelligence and big data analytics, are helping to streamline and automate critical aspects of the screening and monitoring processes, with the advent to advancements in technology and telecommunication networks boosting the global ophthalmic telemedicine market.
Therapeutic Indication Outlook:
Based on therapeutic indication, the ophthalmic telemedicine market is segmented into diabetic retinopathy, glaucoma, age-related macular degeneration, retinopathy of prematurity (ROP) and others. Age-related macular degeneration is estimated to be the fastest growing therapeutic indication over the forecast period. Over the last few years, the use of ophthalmic telemedicine for patients with age-related macular degeneration has advanced dramatically. Globally, age-related macular degeneration is the most common cause of central vision loss. Telemedicine is being adopted on a large scale for early detection of age-related macular degeneration for large communities and remote places to have access to better treatments. Thus, telemedicine for ophthalmology is gaining immense significance globally.
Application Outlook:
Based on application, the global ophthalmic telemedicine market is segmented into vision testing, diagnosis and consultation, education and training and others. Diagnosis and consultation had the highest share in the market in 2021. Ophthalmic telemedicine is proving to be a good solution for delivering high-quality medical care to the rural population, particularly in isolated places. Major players in the market are introducing cloud based platforms for remote diagnosis and consultation for ophthalmic treatments. For instance, Retina Labs developed their e-consultation platform based on telemedicine and dedicated to eye health. This platform helps ophthalmologists to connect with their patients virtually for diagnosis and consultations.
End User Outlook:
Based on end user, the ophthalmic telemedicine market is segmented into hospitals, ophthalmology clinics, others. Hospitals as end users held the highest share in the global market in 2021. Hospitals have reacted quickly to improve telemedicine tactics and virtual healthcare services to replace normal care, including patient follow-up, home monitoring, and forward triage and management of new patients before their visit to ophthalmology departments. Moreover hospitals have widely adopted ophthalmic telemedicine during the pandemic as patients couldn’t visit their doctors frequently for follow-up, check-ups or treatments. Additionally, the government organizations and hospitals are looking forward to invest into telemedicine products and solutions to provide the patients with easier and faster communication to have better results for their treatments.
Region Outlook:
North America had the highest share in the global ophthalmic telemedicine market in 2021. There has been an increasing prevalence of eye problems among the geriatric population such as diabetic retinopathy and macular degeneration in United States and Canada. A large number of patients in United States are opting for home care monitoring and treatments, which has led to an increased demand for ophthalmic telemedicine over the last few years. Furthermore, the increased investments in research and development for ophthalmic telemedicine devices and solutions by the leading players in the market is boosting the growth ophthalmic telemedicine market in North America.
Competitive Landscape
The report provides both, qualitative and quantitative research of ophthalmic telemedicine market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analysed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global ophthalmic telemedicine market are:
- Capri Healthcare
- Care1 Telemedicine
- Doxy.me Inc.
- EyecareLive, Inc
- EyePACS, Inc.
- Forus Health Pvt Ltd
- Pulse Telemedicine Technologies
- Secure Diagnostic Imaging Ltd.
- Smart Vision Labs
- Spect Inc.
- ZEISS International
- Other Market Participants
Global Ophthalmic Telemedicine Market:
- By Component
- Hardware
- Platform/Solutions
- Services
- By Therapeutic Indication
- Diabetic Retinopathy
- Glaucoma
- Age-Related Macular Degeneration
- Retinopathy of Prematurity (ROP)
- Others
- By Application
- Vision Testing
- Diagnosis and Consultation
- Education and Training
- Others
- By End Users
- Hospitals
- Ophthalmology Clinics
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market
Segmentation
1.2. Years
Considered
1.2.1. Historic
Years: 2015 - 2019
1.2.2. Base
Year: 2020
1.2.3. Forecast
Years: 2021 – 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary
Research
3.1.1. Research
Questionnaire
3.1.2. Global
Percentage Breakdown
3.1.3. Primary
Interviews: Key Opinion Leaders (KOLs)
3.2. Secondary
Research
3.2.1. Paid
Databases
3.2.2. Secondary
Sources
3.3. Market
Size Estimates
3.3.1. Top-Down
Approach
3.3.2. Bottom-Up
Approach
3.4. Data
Triangulation Methodology
3.5. Research
Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Ophthalmic Telemedicine Market
6. Market Synopsis:
Ophthalmic Telemedicine Market
7. Ophthalmic Telemedicine Market Analysis: Qualitative
Perspective
7.1. Introduction
7.1.1. Product
Definition
7.1.2. Industry
Development
7.2. Market
Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in
Ophthalmic Telemedicine Market
7.4. Market
Determinants Radar Chart
7.5. Macro-Economic
and Micro-Economic Indicators: Ophthalmic Telemedicine Market
7.6. Porter’s
Five Force Analysis
7.7. Impact of
Covid-19 on Ophthalmic Telemedicine Market
8. Global Ophthalmic Telemedicine Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global
Ophthalmic Telemedicine Market Revenue (US$ Mn)
8.2. Global
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Component
8.2.1. Hardware
8.2.1.1. Definition
8.2.1.2. Market Estimation and Penetration, 2015 - 2020
8.2.1.3. Market Forecast, 2021 - 2029
8.2.1.4. Compound Annual Growth Rate (CAGR)
8.2.1.5. Regional Bifurcation
8.2.1.5.1. North America
8.2.1.5.1.1. Market
Estimation, 2015 - 2020
8.2.1.5.1.2. Market
Forecast, 2021 - 2029
8.2.1.5.2. Europe
8.2.1.5.2.1. Market
Estimation, 2015 - 2020
8.2.1.5.2.2. Market
Forecast, 2021 - 2029
8.2.1.5.3. Asia Pacific
8.2.1.5.3.1. Market
Estimation, 2015 - 2020
8.2.1.5.3.2. Market
Forecast, 2021 - 2029
8.2.1.5.4. Middle East and Africa
8.2.1.5.4.1. Market
Estimation, 2015 - 2020
8.2.1.5.4.2. Market
Forecast, 2021 - 2029
8.2.1.5.5. Latin America
8.2.1.5.5.1. Market
Estimation, 2015 - 2020
8.2.1.5.5.2. Market
Forecast, 2021 - 2029
8.2.2. Platform/Solutions
8.2.2.1. Definition
8.2.2.2. Market Estimation and Penetration, 2015 - 2020
8.2.2.3. Market Forecast, 2021 - 2029
8.2.2.4. Compound Annual Growth Rate (CAGR)
8.2.2.5. Regional Bifurcation
8.2.2.5.1. North America
8.2.2.5.1.1. Market
Estimation, 2015 - 2020
8.2.2.5.1.2. Market
Forecast, 2021 - 2029
8.2.2.5.2. Europe
8.2.2.5.2.1. Market
Estimation, 2015 - 2020
8.2.2.5.2.2. Market
Forecast, 2021 - 2029
8.2.2.5.3. Asia Pacific
8.2.2.5.3.1. Market
Estimation, 2015 - 2020
8.2.2.5.3.2. Market
Forecast, 2021 - 2029
8.2.2.5.4. Middle East and Africa
8.2.2.5.4.1. Market
Estimation, 2015 - 2020
8.2.2.5.4.2. Market
Forecast, 2021 - 2029
8.2.2.5.5. Latin America
8.2.2.5.5.1. Market
Estimation, 2015 - 2020
8.2.2.5.5.2. Market
Forecast, 2021 - 2029
8.2.3. Services
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2015 - 2020
8.2.3.3. Market Forecast, 2021 - 2029
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market
Estimation, 2015 - 2020
8.2.3.5.1.2. Market
Forecast, 2021 - 2029
8.2.3.5.2. Europe
8.2.3.5.2.1. Market
Estimation, 2015 - 2020
8.2.3.5.2.2. Market
Forecast, 2021 - 2029
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market
Estimation, 2015 - 2020
8.2.3.5.3.2. Market
Forecast, 2021 - 2029
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market
Estimation, 2015 - 2020
8.2.3.5.4.2. Market
Forecast, 2021 - 2029
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market
Estimation, 2015 - 2020
8.2.3.5.5.2. Market
Forecast, 2021 - 2029
8.3. Key
Segment for Channeling Investments
8.3.1. By
Component
9. Global Ophthalmic Telemedicine Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
9.2.1. Diabetic
Retinopathy
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2015 - 2020
9.2.1.3. Market Forecast, 2021 - 2029
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market
Estimation, 2015 - 2020
9.2.1.5.1.2. Market
Forecast, 2021 - 2029
9.2.1.5.2. Europe
9.2.1.5.2.1. Market
Estimation, 2015 - 2020
9.2.1.5.2.2. Market
Forecast, 2021 - 2029
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market
Estimation, 2015 - 2020
9.2.1.5.3.2. Market
Forecast, 2021 - 2029
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market
Estimation, 2015 - 2020
9.2.1.5.4.2. Market
Forecast, 2021 - 2029
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market
Estimation, 2015 - 2020
9.2.1.5.5.2. Market
Forecast, 2021 - 2029
9.2.2. Glaucoma
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2015 - 2020
9.2.2.3. Market Forecast, 2021 - 2029
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market
Estimation, 2015 - 2020
9.2.2.5.1.2. Market
Forecast, 2021 - 2029
9.2.2.5.2. Europe
9.2.2.5.2.1. Market
Estimation, 2015 - 2020
9.2.2.5.2.2. Market
Forecast, 2021 - 2029
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market
Estimation, 2015 - 2020
9.2.2.5.3.2. Market
Forecast, 2021 - 2029
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market
Estimation, 2015 - 2020
9.2.2.5.4.2. Market
Forecast, 2021 - 2029
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market
Estimation, 2015 - 2020
9.2.2.5.5.2. Market
Forecast, 2021 - 2029
9.2.3. Age-Related
Macular Degeneration
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2015 - 2020
9.2.3.3. Market Forecast, 2021 - 2029
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market
Estimation, 2015 - 2020
9.2.3.5.1.2. Market
Forecast, 2021 - 2029
9.2.3.5.2. Europe
9.2.3.5.2.1. Market
Estimation, 2015 - 2020
9.2.3.5.2.2. Market
Forecast, 2021 - 2029
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market
Estimation, 2015 - 2020
9.2.3.5.3.2. Market
Forecast, 2021 - 2029
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market
Estimation, 2015 - 2020
9.2.3.5.4.2. Market
Forecast, 2021 - 2029
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market
Estimation, 2015 - 2020
9.2.3.5.5.2. Market
Forecast, 2021 - 2029
9.2.4. Retinopathy
of Prematurity (ROP)
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2015 - 2020
9.2.4.3. Market Forecast, 2021 - 2029
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market
Estimation, 2015 - 2020
9.2.4.5.1.2. Market
Forecast, 2021 - 2029
9.2.4.5.2. Europe
9.2.4.5.2.1. Market
Estimation, 2015 - 2020
9.2.4.5.2.2. Market
Forecast, 2021 - 2029
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market
Estimation, 2015 - 2020
9.2.4.5.3.2. Market
Forecast, 2021 - 2029
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market
Estimation, 2015 - 2020
9.2.4.5.4.2. Market
Forecast, 2021 - 2029
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market
Estimation, 2015 - 2020
9.2.4.5.5.2. Market
Forecast, 2021 - 2029
9.2.5. Others
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2015 - 2020
9.2.5.3. Market Forecast, 2021 - 2029
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market
Estimation, 2015 - 2020
9.2.5.5.1.2. Market
Forecast, 2021 - 2029
9.2.5.5.2. Europe
9.2.5.5.2.1. Market
Estimation, 2015 - 2020
9.2.5.5.2.2. Market
Forecast, 2021 - 2029
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market
Estimation, 2015 - 2020
9.2.5.5.3.2. Market
Forecast, 2021 - 2029
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market
Estimation, 2015 - 2020
9.2.5.5.4.2. Market
Forecast, 2021 - 2029
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market
Estimation, 2015 - 2020
9.2.5.5.5.2. Market
Forecast, 2021 - 2029
9.3. Key
Segment for Channeling Investments
9.3.1. By
Therapeutic Indication
10. Global Ophthalmic Telemedicine Market Analysis and Forecasts,
2021 – 2029
10.1. Overview
10.2. Global
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Application
10.2.1. Vision
Testing
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 - 2020
10.2.1.3. Market Forecast, 2021 - 2029
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market
Estimation, 2015 - 2020
10.2.1.5.1.2. Market
Forecast, 2021 - 2029
10.2.1.5.2. Europe
10.2.1.5.2.1. Market
Estimation, 2015 - 2020
10.2.1.5.2.2. Market
Forecast, 2021 - 2029
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market
Estimation, 2015 - 2020
10.2.1.5.3.2. Market
Forecast, 2021 - 2029
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market
Estimation, 2015 - 2020
10.2.1.5.4.2. Market
Forecast, 2021 - 2029
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market
Estimation, 2015 - 2020
10.2.1.5.5.2. Market
Forecast, 2021 - 2029
10.2.2. Diagnosis
and Consultation
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 - 2020
10.2.2.3. Market Forecast, 2021 - 2029
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market
Estimation, 2015 - 2020
10.2.2.5.1.2. Market
Forecast, 2021 - 2029
10.2.2.5.2. Europe
10.2.2.5.2.1. Market
Estimation, 2015 - 2020
10.2.2.5.2.2. Market
Forecast, 2021 - 2029
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market
Estimation, 2015 - 2020
10.2.2.5.3.2. Market
Forecast, 2021 - 2029
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market
Estimation, 2015 - 2020
10.2.2.5.4.2. Market
Forecast, 2021 - 2029
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market
Estimation, 2015 - 2020
10.2.2.5.5.2. Market
Forecast, 2021 - 2029
10.2.3. Education
and Training
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 - 2020
10.2.3.3. Market Forecast, 2021 - 2029
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market
Estimation, 2015 - 2020
10.2.3.5.1.2. Market
Forecast, 2021 - 2029
10.2.3.5.2. Europe
10.2.3.5.2.1. Market
Estimation, 2015 - 2020
10.2.3.5.2.2. Market
Forecast, 2021 - 2029
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market
Estimation, 2015 - 2020
10.2.3.5.3.2. Market
Forecast, 2021 - 2029
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market
Estimation, 2015 - 2020
10.2.3.5.4.2. Market
Forecast, 2021 - 2029
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market
Estimation, 2015 - 2020
10.2.3.5.5.2. Market
Forecast, 2021 - 2029
10.2.4. Others
10.2.4.1. Definition
10.2.4.2. Market Estimation and Penetration, 2015 - 2020
10.2.4.3. Market Forecast, 2021 - 2029
10.2.4.4. Compound Annual Growth Rate (CAGR)
10.2.4.5. Regional Bifurcation
10.2.4.5.1. North America
10.2.4.5.1.1. Market
Estimation, 2015 - 2020
10.2.4.5.1.2. Market
Forecast, 2021 - 2029
10.2.4.5.2. Europe
10.2.4.5.2.1. Market
Estimation, 2015 - 2020
10.2.4.5.2.2. Market
Forecast, 2021 - 2029
10.2.4.5.3. Asia Pacific
10.2.4.5.3.1. Market
Estimation, 2015 - 2020
10.2.4.5.3.2. Market
Forecast, 2021 - 2029
10.2.4.5.4. Middle East and Africa
10.2.4.5.4.1. Market
Estimation, 2015 - 2020
10.2.4.5.4.2. Market
Forecast, 2021 - 2029
10.2.4.5.5. Latin America
10.2.4.5.5.1. Market
Estimation, 2015 - 2020
10.2.4.5.5.2. Market
Forecast, 2021 - 2029
10.3. Key
Segment for Channeling Investments
10.3.1. By
Application
11. Global Ophthalmic Telemedicine Market Analysis and Forecasts,
2021 – 2029
11.1. Overview
11.2. Global
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By End Users
11.2.1. Hospitals
11.2.1.1. Definition
11.2.1.2. Market Estimation and Penetration, 2015 - 2020
11.2.1.3. Market Forecast, 2021 - 2029
11.2.1.4. Compound Annual Growth Rate (CAGR)
11.2.1.5. Regional Bifurcation
11.2.1.5.1. North America
11.2.1.5.1.1. Market
Estimation, 2015 - 2020
11.2.1.5.1.2. Market
Forecast, 2021 - 2029
11.2.1.5.2. Europe
11.2.1.5.2.1. Market
Estimation, 2015 - 2020
11.2.1.5.2.2. Market
Forecast, 2021 - 2029
11.2.1.5.3. Asia Pacific
11.2.1.5.3.1. Market
Estimation, 2015 - 2020
11.2.1.5.3.2. Market
Forecast, 2021 - 2029
11.2.1.5.4. Middle East and Africa
11.2.1.5.4.1. Market
Estimation, 2015 - 2020
11.2.1.5.4.2. Market
Forecast, 2021 - 2029
11.2.1.5.5. Latin America
11.2.1.5.5.1. Market
Estimation, 2015 - 2020
11.2.1.5.5.2. Market
Forecast, 2021 - 2029
11.2.2. Ophthalmology
Clinics
11.2.2.1. Definition
11.2.2.2. Market Estimation and Penetration, 2015 - 2020
11.2.2.3. Market Forecast, 2021 - 2029
11.2.2.4. Compound Annual Growth Rate (CAGR)
11.2.2.5. Regional Bifurcation
11.2.2.5.1. North America
11.2.2.5.1.1. Market
Estimation, 2015 - 2020
11.2.2.5.1.2. Market
Forecast, 2021 - 2029
11.2.2.5.2. Europe
11.2.2.5.2.1. Market
Estimation, 2015 - 2020
11.2.2.5.2.2. Market
Forecast, 2021 - 2029
11.2.2.5.3. Asia Pacific
11.2.2.5.3.1. Market
Estimation, 2015 - 2020
11.2.2.5.3.2. Market
Forecast, 2021 - 2029
11.2.2.5.4. Middle East and Africa
11.2.2.5.4.1. Market
Estimation, 2015 - 2020
11.2.2.5.4.2. Market
Forecast, 2021 - 2029
11.2.2.5.5. Latin America
11.2.2.5.5.1. Market
Estimation, 2015 - 2020
11.2.2.5.5.2. Market
Forecast, 2021 - 2029
11.2.3. Others
11.2.3.1. Definition
11.2.3.2. Market Estimation and Penetration, 2015 - 2020
11.2.3.3. Market Forecast, 2021 - 2029
11.2.3.4. Compound Annual Growth Rate (CAGR)
11.2.3.5. Regional Bifurcation
11.2.3.5.1. North America
11.2.3.5.1.1. Market
Estimation, 2015 - 2020
11.2.3.5.1.2. Market
Forecast, 2021 - 2029
11.2.3.5.2. Europe
11.2.3.5.2.1. Market
Estimation, 2015 - 2020
11.2.3.5.2.2. Market
Forecast, 2021 - 2029
11.2.3.5.3. Asia Pacific
11.2.3.5.3.1. Market
Estimation, 2015 - 2020
11.2.3.5.3.2. Market
Forecast, 2021 - 2029
11.2.3.5.4. Middle East and Africa
11.2.3.5.4.1. Market
Estimation, 2015 - 2020
11.2.3.5.4.2. Market
Forecast, 2021 - 2029
11.2.3.5.5. Latin America
11.2.3.5.5.1. Market
Estimation, 2015 - 2020
11.2.3.5.5.2. Market
Forecast, 2021 - 2029
11.3. Key
Segment for Channeling Investments
11.3.1. By End
Users
12. North America Ophthalmic Telemedicine Market Analysis and
Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn)
12.2. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Component
12.2.1. Hardware
12.2.2. Platform/Solutions
12.2.3. Services
12.3. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
12.3.1. Diabetic
Retinopathy
12.3.2. Glaucoma
12.3.3. Age-Related
Macular Degeneration
12.3.4. Retinopathy
of Prematurity (ROP)
12.3.5. Others
12.4. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Application
12.4.1. Vision
Testing
12.4.2. Diagnosis
and Consultation
12.4.3. Education
and Training
12.4.4. Others
12.5. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By End
Users
12.5.1. Hospitals
12.5.2. Ophthalmology
Clinics
12.5.3. Others
12.6. North
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Country
12.6.1. U.S
12.6.1.1. U.S Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
12.6.1.1.1. Hardware
12.6.1.1.2. Platform/Solutions
12.6.1.1.3. Services
12.6.1.2. U.S Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
12.6.1.2.1. Diabetic Retinopathy
12.6.1.2.2. Glaucoma
12.6.1.2.3. Age-Related Macular Degeneration
12.6.1.2.4. Retinopathy of Prematurity (ROP)
12.6.1.2.5. Others
12.6.1.3. U.S Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.3.1. Vision Testing
12.6.1.3.2. Diagnosis and Consultation
12.6.1.3.3. Education and Training
12.6.1.3.4. Others
12.6.1.4. U.S Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.1.4.1. Hospitals
12.6.1.4.2. Ophthalmology Clinics
12.6.1.4.3. Others
12.6.2. Canada
12.6.2.1. Canada Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
12.6.2.1.1. Hardware
12.6.2.1.2. Platform/Solutions
12.6.2.1.3. Services
12.6.2.2. Canada Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
12.6.2.2.1. Diabetic Retinopathy
12.6.2.2.2. Glaucoma
12.6.2.2.3. Age-Related Macular Degeneration
12.6.2.2.4. Retinopathy of Prematurity (ROP)
12.6.2.2.5. Others
12.6.2.3. Canada Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.2.3.1. Vision Testing
12.6.2.3.2. Diagnosis and Consultation
12.6.2.3.3. Education and Training
12.6.2.3.4. Others
12.6.2.4. Canada Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.2.4.1. Hospitals
12.6.2.4.2. Ophthalmology Clinics
12.6.2.4.3. Others
12.6.3. Mexico
12.6.3.1. Mexico Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
12.6.3.1.1. Hardware
12.6.3.1.2. Platform/Solutions
12.6.3.1.3. Services
12.6.3.2. Mexico Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
12.6.3.2.1. Diabetic Retinopathy
12.6.3.2.2. Glaucoma
12.6.3.2.3. Age-Related Macular Degeneration
12.6.3.2.4. Retinopathy of Prematurity (ROP)
12.6.3.2.5. Others
12.6.3.3. Mexico Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.3.1. Vision Testing
12.6.3.3.2. Diagnosis and Consultation
12.6.3.3.3. Education and Training
12.6.3.3.4. Others
12.6.3.4. Mexico Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
12.6.3.4.1. Hospitals
12.6.3.4.2. Ophthalmology Clinics
12.6.3.4.3. Others
12.6.4. Rest of
North America
12.6.4.1. Rest of North America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Component
12.6.4.1.1. Hardware
12.6.4.1.2. Platform/Solutions
12.6.4.1.3. Services
12.6.4.2. Rest of North America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
12.6.4.2.1. Diabetic Retinopathy
12.6.4.2.2. Glaucoma
12.6.4.2.3. Age-Related Macular Degeneration
12.6.4.2.4. Retinopathy of Prematurity (ROP)
12.6.4.2.5. Others
12.6.4.3. Rest of North America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.4.3.1. Vision Testing
12.6.4.3.2. Diagnosis and Consultation
12.6.4.3.3. Education and Training
12.6.4.3.4. Others
12.6.4.4. Rest of North America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By End Users
12.6.4.4.1. Hospitals
12.6.4.4.2. Ophthalmology Clinics
12.6.4.4.3. Others
12.7. Key
Segment for Channeling Investments
12.7.1. By
Country
12.7.2. By
Component
12.7.3. By
Therapeutic Indication
12.7.4. By
Application
12.7.5. By End
Users
13. Europe Ophthalmic Telemedicine Market Analysis and Forecasts,
2021 - 2029
13.1. Overview
13.1.1. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn)
13.2. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Component
13.2.1. Hardware
13.2.2. Platform/Solutions
13.2.3. Services
13.3. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
13.3.1. Diabetic
Retinopathy
13.3.2. Glaucoma
13.3.3. Age-Related
Macular Degeneration
13.3.4. Retinopathy
of Prematurity (ROP)
13.3.5. Others
13.4. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Application
13.4.1. Vision
Testing
13.4.2. Diagnosis
and Consultation
13.4.3. Education
and Training
13.4.4. Others
13.5. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.1. Hospitals
13.5.2. Ophthalmology
Clinics
13.5.3. Others
13.6. Europe
Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Country
13.6.1. France
13.6.1.1. France Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
13.6.1.1.1. Hardware
13.6.1.1.2. Platform/Solutions
13.6.1.1.3. Services
13.6.1.2. France Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.6.1.2.1. Diabetic Retinopathy
13.6.1.2.2. Glaucoma
13.6.1.2.3. Age-Related Macular Degeneration
13.6.1.2.4. Retinopathy of Prematurity (ROP)
13.6.1.2.5. Others
13.6.1.3. France Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.1.3.1. Vision Testing
13.6.1.3.2. Diagnosis and Consultation
13.6.1.3.3. Education and Training
13.6.1.3.4. Others
13.6.1.4. France Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.1.4.1. Hospitals
13.6.1.4.2. Ophthalmology Clinics
13.6.1.4.3. Others
13.6.2. The UK
13.6.2.1. The UK Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
13.6.2.1.1. Hardware
13.6.2.1.2. Platform/Solutions
13.6.2.1.3. Services
13.6.2.2. The UK Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.6.2.2.1. Diabetic Retinopathy
13.6.2.2.2. Glaucoma
13.6.2.2.3. Age-Related Macular Degeneration
13.6.2.2.4. Retinopathy of Prematurity (ROP)
13.6.2.2.5. Others
13.6.2.3. The UK Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.2.3.1. Vision Testing
13.6.2.3.2. Diagnosis and Consultation
13.6.2.3.3. Education and Training
13.6.2.3.4. Others
13.6.2.4. The UK Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.2.4.1. Hospitals
13.6.2.4.2. Ophthalmology Clinics
13.6.2.4.3. Others
13.6.3. Spain
13.6.3.1. Spain Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
13.6.3.1.1. Hardware
13.6.3.1.2. Platform/Solutions
13.6.3.1.3. Services
13.6.3.2. Spain Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.6.3.2.1. Diabetic Retinopathy
13.6.3.2.2. Glaucoma
13.6.3.2.3. Age-Related Macular Degeneration
13.6.3.2.4. Retinopathy of Prematurity (ROP)
13.6.3.2.5. Others
13.6.3.3. Spain Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.3.3.1. Vision Testing
13.6.3.3.2. Diagnosis and Consultation
13.6.3.3.3. Education and Training
13.6.3.3.4. Others
13.6.3.4. Spain Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.3.4.1. Hospitals
13.6.3.4.2. Ophthalmology Clinics
13.6.3.4.3. Others
13.6.4. Germany
13.6.4.1. Germany Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
13.6.4.1.1. Hardware
13.6.4.1.2. Platform/Solutions
13.6.4.1.3. Services
13.6.4.2. Germany Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.6.4.2.1. Diabetic Retinopathy
13.6.4.2.2. Glaucoma
13.6.4.2.3. Age-Related Macular Degeneration
13.6.4.2.4. Retinopathy of Prematurity (ROP)
13.6.4.2.5. Others
13.6.4.3. Germany Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.4.3.1. Vision Testing
13.6.4.3.2. Diagnosis and Consultation
13.6.4.3.3. Education and Training
13.6.4.3.4. Others
13.6.4.4. Germany Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.4.4.1. Hospitals
13.6.4.4.2. Ophthalmology Clinics
13.6.4.4.3. Others
13.6.5. Italy
13.6.5.1. Italy Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
13.6.5.1.1. Hardware
13.6.5.1.2. Platform/Solutions
13.6.5.1.3. Services
13.6.5.2. Italy Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
13.6.5.2.1. Diabetic Retinopathy
13.6.5.2.2. Glaucoma
13.6.5.2.3. Age-Related Macular Degeneration
13.6.5.2.4. Retinopathy of Prematurity (ROP)
13.6.5.2.5. Others
13.6.5.3. Italy Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.5.3.1. Vision Testing
13.6.5.3.2. Diagnosis and Consultation
13.6.5.3.3. Education and Training
13.6.5.3.4. Others
13.6.5.4. Italy Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
13.6.5.4.1. Hospitals
13.6.5.4.2. Ophthalmology Clinics
13.6.5.4.3. Others
13.6.6. Nordic
Countries
13.6.6.1. Nordic Countries Ophthalmic Telemedicine Market Revenue (US$
Mn) and Forecasts, By Component
13.6.6.1.1. Hardware
13.6.6.1.2. Platform/Solutions
13.6.6.1.3. Services
13.6.6.2. Nordic Countries Ophthalmic Telemedicine Market Revenue (US$
Mn) and Forecasts, By Therapeutic Indication
13.6.6.2.1. Diabetic Retinopathy
13.6.6.2.2. Glaucoma
13.6.6.2.3. Age-Related Macular Degeneration
13.6.6.2.4. Retinopathy of Prematurity (ROP)
13.6.6.2.5. Others
13.6.6.3. Nordic Countries Ophthalmic Telemedicine Market Revenue (US$
Mn) and Forecasts, By Application
13.6.6.3.1. Vision Testing
13.6.6.3.2. Diagnosis and Consultation
13.6.6.3.3. Education and Training
13.6.6.3.4. Others
13.6.6.4. Nordic Countries Ophthalmic Telemedicine Market Revenue (US$
Mn) and Forecasts, By End Users
13.6.6.4.1. Hospitals
13.6.6.4.2. Ophthalmology Clinics
13.6.6.4.3. Others
13.6.6.5. Nordic Countries Ophthalmic Telemedicine Market Revenue (US$
Mn) and Forecasts, By Country
13.6.6.5.1. Denmark
13.6.6.5.2. Finland
13.6.6.5.3. Iceland
13.6.6.5.4. Sweden
13.6.6.5.5. Norway
13.6.7. Benelux
Union
13.6.7.1. Benelux Union Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
13.6.7.1.1. Hardware
13.6.7.1.2. Platform/Solutions
13.6.7.1.3. Services
13.6.7.2. Benelux Union Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
13.6.7.2.1. Diabetic Retinopathy
13.6.7.2.2. Glaucoma
13.6.7.2.3. Age-Related Macular Degeneration
13.6.7.2.4. Retinopathy of Prematurity (ROP)
13.6.7.2.5. Others
13.6.7.3. Benelux Union Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.7.3.1. Vision Testing
13.6.7.3.2. Diagnosis and Consultation
13.6.7.3.3. Education and Training
13.6.7.3.4. Others
13.6.7.4. Benelux Union Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.7.4.1. Hospitals
13.6.7.4.2. Ophthalmology Clinics
13.6.7.4.3. Others
13.6.7.5. Benelux Union Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1. Belgium
13.6.7.5.2. The Netherlands
13.6.7.5.3. Luxembourg
13.6.8. Rest of
Europe
13.6.8.1. Rest of Europe Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
13.6.8.1.1. Hardware
13.6.8.1.2. Platform/Solutions
13.6.8.1.3. Services
13.6.8.2. Rest of Europe Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
13.6.8.2.1. Diabetic Retinopathy
13.6.8.2.2. Glaucoma
13.6.8.2.3. Age-Related Macular Degeneration
13.6.8.2.4. Retinopathy of Prematurity (ROP)
13.6.8.2.5. Others
13.6.8.3. Rest of Europe Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.8.3.1. Vision Testing
13.6.8.3.2. Diagnosis and Consultation
13.6.8.3.3. Education and Training
13.6.8.3.4. Others
13.6.8.4. Rest of Europe Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
13.6.8.4.1. Hospitals
13.6.8.4.2. Ophthalmology Clinics
13.6.8.4.3. Others
13.7. Key
Segment for Channeling Investments
13.7.1. By
Country
13.7.2. By
Component
13.7.3. By
Therapeutic Indication
13.7.4. By
Application
13.7.5. By End
Users
14. Asia Pacific Ophthalmic Telemedicine Market Analysis and
Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn)
14.2. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Component
14.2.1. Hardware
14.2.2. Platform/Solutions
14.2.3. Services
14.3. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
14.3.1. Diabetic
Retinopathy
14.3.2. Glaucoma
14.3.3. Age-Related
Macular Degeneration
14.3.4. Retinopathy
of Prematurity (ROP)
14.3.5. Others
14.4. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Application
14.4.1. Vision
Testing
14.4.2. Diagnosis
and Consultation
14.4.3. Education
and Training
14.4.4. Others
14.5. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By End
Users
14.5.1. Hospitals
14.5.2. Ophthalmology
Clinics
14.5.3. Others
14.6. Asia
Pacific Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Country
14.6.1. China
14.6.1.1. China Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
14.6.1.1.1. Hardware
14.6.1.1.2. Platform/Solutions
14.6.1.1.3. Services
14.6.1.2. China Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.6.1.2.1. Diabetic Retinopathy
14.6.1.2.2. Glaucoma
14.6.1.2.3. Age-Related Macular Degeneration
14.6.1.2.4. Retinopathy of Prematurity (ROP)
14.6.1.2.5. Others
14.6.1.3. China Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.1.3.1. Vision Testing
14.6.1.3.2. Diagnosis and Consultation
14.6.1.3.3. Education and Training
14.6.1.3.4. Others
14.6.1.4. China Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.1.4.1. Hospitals
14.6.1.4.2. Ophthalmology Clinics
14.6.1.4.3. Others
14.6.2. Japan
14.6.2.1. Japan Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
14.6.2.1.1. Hardware
14.6.2.1.2. Platform/Solutions
14.6.2.1.3. Services
14.6.2.2. Japan Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.6.2.2.1. Diabetic Retinopathy
14.6.2.2.2. Glaucoma
14.6.2.2.3. Age-Related Macular Degeneration
14.6.2.2.4. Retinopathy of Prematurity (ROP)
14.6.2.2.5. Others
14.6.2.3. Japan Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.2.3.1. Vision Testing
14.6.2.3.2. Diagnosis and Consultation
14.6.2.3.3. Education and Training
14.6.2.3.4. Others
14.6.2.4. Japan Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.2.4.1. Hospitals
14.6.2.4.2. Ophthalmology Clinics
14.6.2.4.3. Others
14.6.3. India
14.6.3.1. India Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
14.6.3.1.1. Hardware
14.6.3.1.2. Platform/Solutions
14.6.3.1.3. Services
14.6.3.2. India Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.6.3.2.1. Diabetic Retinopathy
14.6.3.2.2. Glaucoma
14.6.3.2.3. Age-Related Macular Degeneration
14.6.3.2.4. Retinopathy of Prematurity (ROP)
14.6.3.2.5. Others
14.6.3.3. India Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.3.3.1. Vision Testing
14.6.3.3.2. Diagnosis and Consultation
14.6.3.3.3. Education and Training
14.6.3.3.4. Others
14.6.3.4. India Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.3.4.1. Hospitals
14.6.3.4.2. Ophthalmology Clinics
14.6.3.4.3. Others
14.6.4. New
Zealand
14.6.4.1. New Zealand Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
14.6.4.1.1. Hardware
14.6.4.1.2. Platform/Solutions
14.6.4.1.3. Services
14.6.4.2. New Zealand Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
14.6.4.2.1. Diabetic Retinopathy
14.6.4.2.2. Glaucoma
14.6.4.2.3. Age-Related Macular Degeneration
14.6.4.2.4. Retinopathy of Prematurity (ROP)
14.6.4.2.5. Others
14.6.4.3. New Zealand Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.4.3.1. Vision Testing
14.6.4.3.2. Diagnosis and Consultation
14.6.4.3.3. Education and Training
14.6.4.3.4. Others
14.6.4.4. New Zealand Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.4.4.1. Hospitals
14.6.4.4.2. Ophthalmology Clinics
14.6.4.4.3. Others
14.6.5. Australia
14.6.5.1. Australia Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
14.6.5.1.1. Hardware
14.6.5.1.2. Platform/Solutions
14.6.5.1.3. Services
14.6.5.2. Australia Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
14.6.5.2.1. Diabetic Retinopathy
14.6.5.2.2. Glaucoma
14.6.5.2.3. Age-Related Macular Degeneration
14.6.5.2.4. Retinopathy of Prematurity (ROP)
14.6.5.2.5. Others
14.6.5.3. Australia Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.5.3.1. Vision Testing
14.6.5.3.2. Diagnosis and Consultation
14.6.5.3.3. Education and Training
14.6.5.3.4. Others
14.6.5.4. Australia Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
14.6.5.4.1. Hospitals
14.6.5.4.2. Ophthalmology Clinics
14.6.5.4.3. Others
14.6.6. South
Korea
14.6.6.1. South Korea Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
14.6.6.1.1. Hardware
14.6.6.1.2. Platform/Solutions
14.6.6.1.3. Services
14.6.6.2. South Korea Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
14.6.6.2.1. Diabetic Retinopathy
14.6.6.2.2. Glaucoma
14.6.6.2.3. Age-Related Macular Degeneration
14.6.6.2.4. Retinopathy of Prematurity (ROP)
14.6.6.2.5. Others
14.6.6.3. South Korea Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.6.3.1. Vision Testing
14.6.6.3.2. Diagnosis and Consultation
14.6.6.3.3. Education and Training
14.6.6.3.4. Others
14.6.6.4. South Korea Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.6.4.1. Hospitals
14.6.6.4.2. Ophthalmology Clinics
14.6.6.4.3. Others
14.6.7. Southeast
Asia
14.6.7.1. Southeast Asia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
14.6.7.1.1. Hardware
14.6.7.1.2. Platform/Solutions
14.6.7.1.3. Services
14.6.7.2. Southeast Asia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
14.6.7.2.1. Diabetic Retinopathy
14.6.7.2.2. Glaucoma
14.6.7.2.3. Age-Related Macular Degeneration
14.6.7.2.4. Retinopathy of Prematurity (ROP)
14.6.7.2.5. Others
14.6.7.3. Southeast Asia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.7.3.1. Vision Testing
14.6.7.3.2. Diagnosis and Consultation
14.6.7.3.3. Education and Training
14.6.7.3.4. Others
14.6.7.4. Southeast Asia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
14.6.7.4.1. Hospitals
14.6.7.4.2. Ophthalmology Clinics
14.6.7.4.3. Others
14.6.7.5. Southeast Asia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1. Indonesia
14.6.7.5.2. Thailand
14.6.7.5.3. Malaysia
14.6.7.5.4. Singapore
14.6.7.5.5. Rest of Southeast Asia
14.6.8. Rest of
Asia Pacific
14.6.8.1. Rest of Asia Pacific Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Component
14.6.8.1.1. Hardware
14.6.8.1.2. Platform/Solutions
14.6.8.1.3. Services
14.6.8.2. Rest of Asia Pacific Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
14.6.8.2.1. Diabetic Retinopathy
14.6.8.2.2. Glaucoma
14.6.8.2.3. Age-Related Macular Degeneration
14.6.8.2.4. Retinopathy of Prematurity (ROP)
14.6.8.2.5. Others
14.6.8.3. Rest of Asia Pacific Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.8.3.1. Vision Testing
14.6.8.3.2. Diagnosis and Consultation
14.6.8.3.3. Education and Training
14.6.8.3.4. Others
14.6.8.4. Rest of Asia Pacific Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By End Users
14.6.8.4.1. Hospitals
14.6.8.4.2. Ophthalmology Clinics
14.6.8.4.3. Others
14.7. Key
Segment for Channeling Investments
14.7.1. By
Country
14.7.2. By
Component
14.7.3. By
Therapeutic Indication
14.7.4. By
Application
14.7.5. By End
Users
15. Middle East and Africa Ophthalmic Telemedicine Market
Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn)
15.2. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Component
15.2.1. Hardware
15.2.2. Platform/Solutions
15.2.3. Services
15.3. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Therapeutic Indication
15.3.1. Diabetic
Retinopathy
15.3.2. Glaucoma
15.3.3. Age-Related
Macular Degeneration
15.3.4. Retinopathy
of Prematurity (ROP)
15.3.5. Others
15.4. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Application
15.4.1. Vision
Testing
15.4.2. Diagnosis
and Consultation
15.4.3. Education
and Training
15.4.4. Others
15.5. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By End Users
15.5.1. Hospitals
15.5.2. Ophthalmology
Clinics
15.5.3. Others
15.6. Middle
East and Africa Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Country
15.6.1. Saudi
Arabia
15.6.1.1. Saudi Arabia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
15.6.1.1.1. Hardware
15.6.1.1.2. Platform/Solutions
15.6.1.1.3. Services
15.6.1.2. Saudi Arabia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
15.6.1.2.1. Diabetic Retinopathy
15.6.1.2.2. Glaucoma
15.6.1.2.3. Age-Related Macular Degeneration
15.6.1.2.4. Retinopathy of Prematurity (ROP)
15.6.1.2.5. Others
15.6.1.3. Saudi Arabia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.1.3.1. Vision Testing
15.6.1.3.2. Diagnosis and Consultation
15.6.1.3.3. Education and Training
15.6.1.3.4. Others
15.6.1.4. Saudi Arabia Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.1.4.1. Hospitals
15.6.1.4.2. Ophthalmology Clinics
15.6.1.4.3. Others
15.6.2. UAE
15.6.2.1. UAE Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
15.6.2.1.1. Hardware
15.6.2.1.2. Platform/Solutions
15.6.2.1.3. Services
15.6.2.2. UAE Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.6.2.2.1. Diabetic Retinopathy
15.6.2.2.2. Glaucoma
15.6.2.2.3. Age-Related Macular Degeneration
15.6.2.2.4. Retinopathy of Prematurity (ROP)
15.6.2.2.5. Others
15.6.2.3. UAE Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Application
15.6.2.3.1. Vision Testing
15.6.2.3.2. Diagnosis and Consultation
15.6.2.3.3. Education and Training
15.6.2.3.4. Others
15.6.2.4. UAE Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.2.4.1. Hospitals
15.6.2.4.2. Ophthalmology Clinics
15.6.2.4.3. Others
15.6.3. Egypt
15.6.3.1. Egypt Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
15.6.3.1.1. Hardware
15.6.3.1.2. Platform/Solutions
15.6.3.1.3. Services
15.6.3.2. Egypt Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.6.3.2.1. Diabetic Retinopathy
15.6.3.2.2. Glaucoma
15.6.3.2.3. Age-Related Macular Degeneration
15.6.3.2.4. Retinopathy of Prematurity (ROP)
15.6.3.2.5. Others
15.6.3.3. Egypt Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.3.3.1. Vision Testing
15.6.3.3.2. Diagnosis and Consultation
15.6.3.3.3. Education and Training
15.6.3.3.4. Others
15.6.3.4. Egypt Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.3.4.1. Hospitals
15.6.3.4.2. Ophthalmology Clinics
15.6.3.4.3. Others
15.6.4. Kuwait
15.6.4.1. Kuwait Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
15.6.4.1.1. Hardware
15.6.4.1.2. Platform/Solutions
15.6.4.1.3. Services
15.6.4.2. Kuwait Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
15.6.4.2.1. Diabetic Retinopathy
15.6.4.2.2. Glaucoma
15.6.4.2.3. Age-Related Macular Degeneration
15.6.4.2.4. Retinopathy of Prematurity (ROP)
15.6.4.2.5. Others
15.6.4.3. Kuwait Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.4.3.1. Vision Testing
15.6.4.3.2. Diagnosis and Consultation
15.6.4.3.3. Education and Training
15.6.4.3.4. Others
15.6.4.4. Kuwait Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
15.6.4.4.1. Hospitals
15.6.4.4.2. Ophthalmology Clinics
15.6.4.4.3. Others
15.6.5. South
Africa
15.6.5.1. South Africa Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Component
15.6.5.1.1. Hardware
15.6.5.1.2. Platform/Solutions
15.6.5.1.3. Services
15.6.5.2. South Africa Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Therapeutic Indication
15.6.5.2.1. Diabetic Retinopathy
15.6.5.2.2. Glaucoma
15.6.5.2.3. Age-Related Macular Degeneration
15.6.5.2.4. Retinopathy of Prematurity (ROP)
15.6.5.2.5. Others
15.6.5.3. South Africa Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.5.3.1. Vision Testing
15.6.5.3.2. Diagnosis and Consultation
15.6.5.3.3. Education and Training
15.6.5.3.4. Others
15.6.5.4. South Africa Ophthalmic Telemedicine Market Revenue (US$ Mn)
and Forecasts, By End Users
15.6.5.4.1. Hospitals
15.6.5.4.2. Ophthalmology Clinics
15.6.5.4.3. Others
15.6.6. Rest of
Middle East & Africa
15.6.6.1. Rest of Middle East & Africa Ophthalmic Telemedicine
Market Revenue (US$ Mn) and Forecasts, By Component
15.6.6.1.1. Hardware
15.6.6.1.2. Platform/Solutions
15.6.6.1.3. Services
15.6.6.2. Rest of Middle East & Africa Ophthalmic Telemedicine
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.6.6.2.1. Diabetic Retinopathy
15.6.6.2.2. Glaucoma
15.6.6.2.3. Age-Related Macular Degeneration
15.6.6.2.4. Retinopathy of Prematurity (ROP)
15.6.6.2.5. Others
15.6.6.3. Rest of Middle East & Africa Ophthalmic Telemedicine
Market Revenue (US$ Mn) and Forecasts, By Application
15.6.6.3.1. Vision Testing
15.6.6.3.2. Diagnosis and Consultation
15.6.6.3.3. Education and Training
15.6.6.3.4. Others
15.6.6.4. Rest of Middle East & Africa Ophthalmic Telemedicine
Market Revenue (US$ Mn) and Forecasts, By End Users
15.6.6.4.1. Hospitals
15.6.6.4.2. Ophthalmology Clinics
15.6.6.4.3. Others
15.7. Key
Segment for Channeling Investments
15.7.1. By
Country
15.7.2. By
Component
15.7.3. By
Therapeutic Indication
15.7.4. By
Application
15.7.5. By End
Users
16. Latin America Ophthalmic Telemedicine Market Analysis and
Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn)
16.2. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Component
16.2.1. Hardware
16.2.2. Platform/Solutions
16.2.3. Services
16.3. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Therapeutic Indication
16.3.1. Diabetic
Retinopathy
16.3.2. Glaucoma
16.3.3. Age-Related
Macular Degeneration
16.3.4. Retinopathy
of Prematurity (ROP)
16.3.5. Others
16.4. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Application
16.4.1. Vision
Testing
16.4.2. Diagnosis
and Consultation
16.4.3. Education
and Training
16.4.4. Others
16.5. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By End
Users
16.5.1. Hospitals
16.5.2. Ophthalmology
Clinics
16.5.3. Others
16.6. Latin
America Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts, By
Country
16.6.1. Brazil
16.6.1.1. Brazil Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
16.6.1.1.1. Hardware
16.6.1.1.2. Platform/Solutions
16.6.1.1.3. Services
16.6.1.2. Brazil Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
16.6.1.2.1. Diabetic Retinopathy
16.6.1.2.2. Glaucoma
16.6.1.2.3. Age-Related Macular Degeneration
16.6.1.2.4. Retinopathy of Prematurity (ROP)
16.6.1.2.5. Others
16.6.1.3. Brazil Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.1.3.1. Vision Testing
16.6.1.3.2. Diagnosis and Consultation
16.6.1.3.3. Education and Training
16.6.1.3.4. Others
16.6.1.4. Brazil Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.1.4.1. Hospitals
16.6.1.4.2. Ophthalmology Clinics
16.6.1.4.3. Others
16.6.2. Argentina
16.6.2.1. Argentina Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Component
16.6.2.1.1. Hardware
16.6.2.1.2. Platform/Solutions
16.6.2.1.3. Services
16.6.2.2. Argentina Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By Therapeutic Indication
16.6.2.2.1. Diabetic Retinopathy
16.6.2.2.2. Glaucoma
16.6.2.2.3. Age-Related Macular Degeneration
16.6.2.2.4. Retinopathy of Prematurity (ROP)
16.6.2.2.5. Others
16.6.2.3. Argentina Ophthalmic Telemedicine Market Revenue (US$ Mn) and Forecasts,
By Application
16.6.2.3.1. Vision Testing
16.6.2.3.2. Diagnosis and Consultation
16.6.2.3.3. Education and Training
16.6.2.3.4. Others
16.6.2.4. Argentina Ophthalmic Telemedicine Market Revenue (US$ Mn) and
Forecasts, By End Users
16.6.2.4.1. Hospitals
16.6.2.4.2. Ophthalmology Clinics
16.6.2.4.3. Others
16.6.3. Rest of
Latin America
16.6.3.1. Rest of Latin America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Component
16.6.3.1.1. Hardware
16.6.3.1.2. Platform/Solutions
16.6.3.1.3. Services
16.6.3.2. Rest of Latin America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Therapeutic Indication
16.6.3.2.1. Diabetic Retinopathy
16.6.3.2.2. Glaucoma
16.6.3.2.3. Age-Related Macular Degeneration
16.6.3.2.4. Retinopathy of Prematurity (ROP)
16.6.3.2.5. Others
16.6.3.3. Rest of Latin America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.3.3.1. Vision Testing
16.6.3.3.2. Diagnosis and Consultation
16.6.3.3.3. Education and Training
16.6.3.3.4. Others
16.6.3.4. Rest of Latin America Ophthalmic Telemedicine Market Revenue
(US$ Mn) and Forecasts, By End Users
16.6.3.4.1. Hospitals
16.6.3.4.2. Ophthalmology Clinics
16.6.3.4.3. Others
16.7. Key
Segment for Channeling Investments
16.7.1. By
Country
16.7.2. By
Component
16.7.3. By
Therapeutic Indication
16.7.4. By
Application
16.7.5. By End
Users
17. Competitive Benchmarking
17.1. Market
Share Analysis, 2020
17.2. Global
Presence and Growth Strategies
17.2.1. Mergers
and Acquisitions
17.2.2. Product
Launches
17.2.3. Investments
Trends
17.2.4. R&D
Initiatives
18. Player Profiles
18.1. Capri
Healthcare
18.1.1. Company
Details
18.1.2. Company
Overview
18.1.3. Product
Offerings
18.1.4. Key Developments
18.1.5. Financial
Analysis
18.1.6. SWOT
Analysis
18.1.7. Business
Strategies
18.2. Care1
Telemedicine
18.2.1. Company
Details
18.2.2. Company
Overview
18.2.3. Product
Offerings
18.2.4. Key
Developments
18.2.5. Financial
Analysis
18.2.6. SWOT
Analysis
18.2.7. Business Strategies
18.3. Doxy.me Inc.
18.3.1. Company
Details
18.3.2. Company
Overview
18.3.3. Product
Offerings
18.3.4. Key
Developments
18.3.5. Financial
Analysis
18.3.6. SWOT
Analysis
18.3.7. Business
Strategies
18.4. EyecareLive, Inc
18.4.1. Company
Details
18.4.2. Company
Overview
18.4.3. Product
Offerings
18.4.4. Key
Developments
18.4.5. Financial
Analysis
18.4.6. SWOT
Analysis
18.4.7. Business
Strategies
18.5. EyePACS, Inc.
18.5.1. Company
Details
18.5.2. Company
Overview
18.5.3. Product
Offerings
18.5.4. Key
Developments
18.5.5. Financial
Analysis
18.5.6. SWOT
Analysis
18.5.7. Business
Strategies
18.6. Forus Health Pvt Ltd
18.6.1. Company
Details
18.6.2. Company
Overview
18.6.3. Product
Offerings
18.6.4. Key
Developments
18.6.5. Financial
Analysis
18.6.6. SWOT
Analysis
18.6.7. Business
Strategies
18.7. Pulse Telemedicine Technologies
18.7.1. Company
Details
18.7.2. Company
Overview
18.7.3. Product
Offerings
18.7.4. Key
Developments
18.7.5. Financial
Analysis
18.7.6. SWOT
Analysis
18.7.7. Business
Strategies
18.8. Secure Diagnostic Imaging Ltd.
18.8.1. Company
Details
18.8.2. Company
Overview
18.8.3. Product
Offerings
18.8.4. Key
Developments
18.8.5. Financial
Analysis
18.8.6. SWOT
Analysis
18.8.7. Business
Strategies
18.9. Smart Vision Labs
18.9.1. Company
Details
18.9.2. Company
Overview
18.9.3. Product
Offerings
18.9.4. Key
Developments
18.9.5. Financial
Analysis
18.9.6. SWOT
Analysis
18.9.7. Business
Strategies
18.10. Spect Inc.
18.10.1. Company
Details
18.10.2. Company
Overview
18.10.3. Product
Offerings
18.10.4. Key
Developments
18.10.5. Financial
Analysis
18.10.6. SWOT
Analysis
18.10.7. Business
Strategies
18.11. ZEISS International
18.11.1. Company
Details
18.11.2. Company
Overview
18.11.3. Product
Offerings
18.11.4. Key
Developments
18.11.5. Financial
Analysis
18.11.6. SWOT
Analysis
18.11.7. Business
Strategies
18.12. Other Market Participants
19. Key Findings
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.